Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial
Open Access
- 29 July 2024
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (25) , 1789-1798
Abstract
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations.Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).Keywords
Funding Information
- BeiGene
This publication has 13 references indexed in Scilit:
- P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UPHemaSphere, 2023
- Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tooleJHaem, 2023
- The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaClinical Cancer Research, 2021
- WhiMSICAL: A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomesAmerican Journal of Hematology, 2021
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyBlood, 2020
- Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experienceHematological Oncology, 2019
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Analysis and Interpretation of Results Based on Patient-Reported OutcomesValue in Health, 2007
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993